Michael Lishner

Medicine & Life Sciences

1. Multiple Myeloma 100%
2. Pregnancy 99%
3. B-Cell Chronic Lymphocytic Leukemia 70%
4. Neoplasms 56%
5. Fluorescence In Situ Hybridization 54%
6. Non-Hodgkin's Lymphoma 50%
7. First Pregnancy Trimester 42%
8. Lymphoma 40%
9. Tetraspanins 38%
10. Drug Therapy 38%
11. Simvastatin 37%
12. Placenta 35%
13. Breast Neoplasms 35%
14. Therapeutics 33%
15. Hodgkin Disease 31%
16. Cell Line 31%
17. Trophoblasts 28%
18. HSP27 Heat-Shock Proteins 28%
19. Chromosome Aberrations 27%
20. Mothers 26%
21. Doxorubicin 26%
22. Hydroxymethylglutaryl-CoA Reductase Inhibitors 26%
23. Pharmaceutical Preparations 25%
24. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25%
25. Mesenchymal Stem Cells 24%
26. Second Primary Neoplasms 24%
27. Cytogenetics 23%
28. Bone Marrow 23%
29. Enalapril 23%
30. Thrombocytosis 22%
31. Leukocytes 22%
32. Polycythemia Vera 22%
33. Trisomy 22%
34. Hematologic Neoplasms 20%
35. Acute Myeloid Leukemia 20%
36. Trisomy Chromosome 9 20%
37. Acute Coronary Syndrome 19%
38. Cell Movement 19%
39. Leukemia 19%
40. Trisomy Chromosome 8 19%
41. Peptide Initiation Factors 18%
42. Placebos 18%
43. Fetus 18%
44. Aneuploidy 18%
45. Cryoglobulinemia 17%
46. Lipids 17%
47. Apoptosis 16%
48. Type 2 Diabetes Mellitus 16%
49. LDL Cholesterol 16%
50. Coronary Disease 15%